One-step cell-performed nano-encapsulation for vaccine production
Innovative nano-encapsulation technology for antigen vaccines using muNS-Mi protein, enabling adjuvant-free, orally administered vaccines with enhanced stability and bioavailability.
Overview
This pioneering technology leverages cell-performed nano-encapsulation to produce immunoreactive antigens within nanospheres (NS) using the muNS-Mi protein, derived from a virus. These NS preserve the antigen's structural integrity, functioning effectively as adjuvant-free vaccines. The technology supports oral administration, ensuring antigen stability and bioavailability throughout the gastrointestinal tract. Initial trials with SARS-CoV-2 RBD antigens have demonstrated enhanced immunoreactivity, and the approach is adaptable for other pathogens, offering rapid response capabilities.
Technical specifications
Key features:
- Utilizes muNS-Mi protein to form nanospheres that encapsulate antigens while maintaining their conformation and activity.
- Enables simultaneous production and encapsulation within cells, resulting in a cost-effective, one-step process.
- Supports oral vaccine administration with antigens stable against physical-chemical agents.
- Proven scalability from flask to small-scale bioreactors without loss of efficiency in production or purification.
- Successfully tested for safety in various animals with no adverse effects.
Technology readiness level
This technology is currently at TRL 5, having been validated in relevant environments through small-scale trials. Further optimization and pilot trials are underway to enhance production and immunogenicity, with plans for large-scale testing in birds within a 4-5 month timeframe.
About Universidade de Santiago de Compostela
Universidade de Santiago de Compostela is a comprehensive public research university serving Galicia with campuses in Santiago de Compostela and Lugo. Industry engages through open‑access core facilities, co‑located laboratories, and structured channels for sponsored research, consulting, and bespoke testing. Clinical translation benefits from integration with the regional health service and university hospitals in Santiago, while the Lugo campus offers access to field sites and pilot environments linked to the region’s primary industries. Research is supported by competitive European Union and Spanish national funding. A dedicated technology transfer office manages IP, licensing, and spinout formation, connecting startups to regional incubators and investors.
delivered to your inbox.